Stock Research for BLUE

BLUE

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

BLUE Stock Chart & Research Data

The BLUE chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLUE chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


BLUE Due diligence Resources & Stock Charts

The BLUE stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View BLUE Detailed Price Forecast - CNN Money CNN View BLUE Detailed Summary - Google Finance
Yahoo View BLUE Detailed Summary - Yahoo! Finance Zacks View BLUE Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View BLUE Trends & Analysis - Trade-Ideas Barrons View BLUE Major Holders - Barrons
NASDAQ View BLUE Call Transcripts - NASDAQ Seeking View BLUE Breaking News & Analysis - Seeking Alpha
Spotlight View BLUE Annual Report - CompanySpotlight.com OTC Report View BLUE OTC Short Report - OTCShortReport.com
TradeKing View BLUE Fundamentals - TradeKing Charts View BLUE SEC Filings - Bar Chart
WSJ View Historical Prices for BLUE - The WSJ Morningstar View Performance/Total Return for BLUE - Morningstar
MarketWatch View the Analyst Estimates for BLUE - MarketWatch CNBC View the Earnings History for BLUE - CNBC
StockMarketWatch View the BLUE Earnings - StockMarketWatch MacroAxis View BLUE Buy or Sell Recommendations - MacroAxis
Bullish View the BLUE Bullish Patterns - American Bulls Short Pains View BLUE Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View BLUE Stock Mentions - StockTwits PennyStocks View BLUE Stock Mentions - PennyStockTweets
Twitter View BLUE Stock Mentions - Twitter Invest Hub View BLUE Investment Forum News - Investor Hub
Yahoo View BLUE Stock Mentions - Yahoo! Message Board Seeking Alpha View BLUE Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for BLUE - SECform4.com Insider Cow View Insider Transactions for BLUE - Insider Cow
CNBC View BLUE Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for BLUE - OTC Markets
Yahoo View Insider Transactions for BLUE - Yahoo! Finance NASDAQ View Institutional Holdings for BLUE - NASDAQ


Stock Charts

FinViz View BLUE Stock Insight & Charts - FinViz.com StockCharts View BLUE Investment Charts - StockCharts.com
BarChart View BLUE Stock Overview & Charts - BarChart Trading View View BLUE User Generated Charts - Trading View


Latest Financial News for BLUE

Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives
Posted on Saturday June 23, 2018

Evercore ISI's Josh Schimmer on June 19 upgraded bluebird from In-line to Outperform with a price target lifted from $175 to $230. Bluebird's recent updates related to its LentiGlobin investigational gene therapy in patients with sickle cell disease and the separate myeloma CAR-T therapy bb2121 with its partner Celgene Corporation (NASDAQ: CELG) represent an "important positive inflection" for the company, Schimmer said in the upgrade note.


Today's Research Reports on Trending Tickers: bluebird bio and Exelixis
Posted on Thursday June 21, 2018

NEW YORK, NY / ACCESSWIRE / June 21, 2018 / U.S. markets were mixed Wednesday as global trade concerns continue to be a focus. The Nasdaq and S&P 500 Index posted gains driven by deal making activities ...


Blog Exposure - bluebird bio Announces Encouraging New Data from Northstar (HGB-204) and Northstar-2 (HGB-207) Studies of LentiGlobin(TM) Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Posted on Tuesday June 19, 2018

LONDON, UK / ACCESSWIRE / June 19, 2018 / If you want access to our free research report on bluebird bio, Inc. (NASDAQ: BLUE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BLUE as the Company's latest news hit the wire. On June 15, 2018, the Company announced that it will present new data from the completed Phase-1/2 Northstar (HGB-204) study in adolescents and adults with transfusion-dependent β-thalassemia (TDT) and any genotype, and its ongoing, Phase-3 Northstar-2 (HGB-207) multicenter clinical study of LentiGlobin™ investigational gene therapy in patients with TDT and non-β0/β0 genotypes, at the 23rd Annual Congress of the European Hematology Association in Stockholm on June 16, 2018. Active-Investors.com is currently working on the research report for BioPharmX Corporation (NYSE: BPMX), which also belongs to the Healthcare sector as the Company bluebird bio.


Free Technical Research on BioPharmX and Three More Biotech Equities bio
Posted on Tuesday June 19, 2018

LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on BPMX sign up now at www.wallstequities.com/registration. On Monday, June 18, 2018, the Dow Jones Industrial Average and the S&P 500 edged 0.41% and 0.21% lower, respectively at the closing bell, while the NASDAQ Composite stayed bullish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), BioPharmX Corp. (NYSE AMER: BPMX), BioTime Inc. (NYSE AMER: BTX), and bluebird bio Inc. (NASDAQ: BLUE).


Enter a stock symbol to view the stock details.